The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ:SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those ...
SAB-142 shows favorable safety and pharmacodynamic activity in Phase 1 trial, advancing to Phase 2b for type 1 diabetes. SAB BIO announced positive results from its Phase 1 trial of SAB-142, a novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback